Aligos Therapeutics (NASDAQ:ALGS) Posts Earnings Results, Misses Estimates By $0.78 EPS

Aligos Therapeutics (NASDAQ:ALGS) released its quarterly earnings results on Monday. The company reported ($3.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.63) by ($0.78), Zacks reports. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $11.60 on Monday. The company has a market capitalization of $41.60 million, a PE ratio of -0.89 and a beta of 2.52. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $46.80. The company’s 50 day moving average price is $27.25 and its 200 day moving average price is $20.58.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).